| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-23484SS | |||
| Azide and BSA Free | NBP2-81015 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-724SS | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Allophycocyanin | NB7343APC | |||
| Biotin | NB7343B | |||
| DyLight 350 | NB7343UV | |||
| DyLight 405 | NB7343V | |||
| DyLight 488 | NB7343G | |||
| DyLight 550 | NB7343R | |||
| DyLight 594 | NB7343DL594 | |||
| DyLight 650 | NB7343C | |||
| DyLight 680 | NB7343FR | |||
| DyLight 755 | NB7343IR | |||
| FITC | NB7345 | |||
| HRP | NB7346 | |||
| Janelia Fluor 525 | NB7343JF525 | |||
| Janelia Fluor 669 | NB7343JF669 | |||
| PE | NB7343PE | |||
| PerCP | NB7343PCP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-24821SS | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Allophycocyanin | NB7240APC | |||
| Biotin | NB7240B | |||
| DyLight 350 | NB7240UV | |||
| DyLight 405 | NB7240V | |||
| DyLight 488 | NB7240G | |||
| DyLight 550 | NB7240R | |||
| DyLight 594 | NB7240DL594 | |||
| DyLight 650 | NB7240C | |||
| DyLight 680 | NB7240FR | |||
| DyLight 755 | NB7240IR | |||
| FITC | NB7241 | |||
| HRP | NB7242 | |||
| Janelia Fluor 525 | NB7240JF525 | |||
| Janelia Fluor 669 | NB7240JF669 | |||
| PE | NB7240PE | |||
| PerCP | NB7240PCP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-35334SS | |||
| Azide and BSA Free | NBP2-80623 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-22121SS | |||
| Azide and BSA Free | NBP2-80844 | |||
![Western Blot: ZEB1 Antibody (2A8A6) [NBP2-23484] - CAFs induced miR-33b downregulation and promoted the EMT phenotype in lung cancer cells. The protein expression levels of E-cadherin, Vimentin, ZEB1, Twist1 and Snail1 in the lung cancer cells co-cultured with CAFs were detected by immunoblotting, using GAPDH protein as the loading control. Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.23082), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Western-Blot-NBP2-23484-img0014.jpg "<b>Biological Strategies Validation. </b>Western Blot: ZEB1 Antibody (2A8A6) [NBP2-23484] - CAFs induced miR-33b downregulation and promoted the EMT phenotype in lung cancer cells. The protein expression levels of E-cadherin, Vimentin, ZEB1, Twist1 and Snail1 in the lung cancer cells co-cultured with CAFs were detected by immunoblotting, using GAPDH protein as the loading control. Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.23082), licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: ZEB1 Antibody (2A8A6) [NBP2-23484] - ZEB1 antibody was tested in HeLa cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Immunocytochemistry-Immunofluorescence-NBP2-23484-img0009.jpg)
![Immunohistochemistry: ZEB1 Antibody (2A8A6) [NBP2-23484] - IHC analysis of paraffin-embedded human cervical cancer tissues with DAB staining.](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Immunohistochemistry-NBP2-23484-img0006.jpg)
![Flow Cytometry: ZEB1 Antibody (2A8A6) [NBP2-23484] - An intracellular stain was performed on U-87 cells with ZEB1 [2A8A6] Antibody NBP2-23484AF700 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 700.](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Flow-Cytometry-NBP2-23484-img0012.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: ZEB1 Antibody (2A8A6) [NBP2-23484] - ZEB1 expression was assayed in lung adenocarcinoma cells after transfectionwith miR-33b or miR-NC, anti-miR-33b or anti-miR-NC in H1299 and A549 cells. Image submitted by verified customer review.](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Western-Blot-NBP2-23484-img0013.jpg)
![Immunohistochemistry: ZEB1 Antibody (2A8A6) [NBP2-23484] - IHC analysis of paraffin-embedded human recturm cancer tissues with DAB staining.](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Immunohistochemistry-NBP2-23484-img0004.jpg)
![Flow Cytometry: ZEB1 Antibody (2A8A6) [NBP2-23484] - Flow cytometric analysis of Hela cells using ZEB1 mouse mAb (green) and negative control (red).](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Flow-Cytometry-NBP2-23484-img0007.jpg)
![Flow Cytometry: ZEB1 Antibody (2A8A6) [NBP2-23484] - An intracellular stain was performed on with A549 cells with ZEB1 Antibody NBP2-23484PE and a a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to phycoerythrin.](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Flow-Cytometry-NBP2-23484-img0010.jpg)
![Flow Cytometry: ZEB1 Antibody (2A8A6) [NBP2-23484] - An intracellular stain was performed on Jurkat with ZEB1 Antibody (2A8A6) NBP2-23484 and a matched isotype control. Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by Mouse F(ab)2 IgG (H+L) PE-conjugated Antibody (R&D Systems, F0102B)](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Flow-Cytometry-NBP2-23484-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: CTGF/CCN2 Antibody [NB100-724] - CTGF antibody was tested in U2OS cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/CTGF-CCN2-Antibody-Immunocytochemistry-Immunofluorescence-NB100-724-img0004.jpg "Immunocytochemistry/Immunofluorescence: CTGF/CCN2 Antibody [NB100-724] - CTGF antibody was tested in U2OS cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).")
![Immunohistochemistry-Paraffin: CTGF/CCN2 Antibody [NB100-724] - Analysis of a FFPE tissue section of human lymph node using 1:200 dilution of CTGF/CCN2 antibody (NB100-724). The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.](http://images.novusbio.com/fullsize/CTGF-CCN2-Antibody-Immunohistochemistry-Paraffin-NB100-724-img0005.jpg)
![Immunocytochemistry/ Immunofluorescence: CTGF/CCN2 Antibody [NB100-724] - Analysis of astrocyte reactivity, the cytoskeleton & migration rate following treatment with TGF-beta 2 & CCN2/CTGF. (A) GFAP immunoreactivity (green) is increased in murine ON astrocytes following TGF-beta 2 & CCN2/CTGF treatment. Nuclei are stained with Dapi (blue) (B) Western Blot experiments analyses of alpha -actinin protein synthesis in murine ON astrocytes after the treatment with 1 ng/ml TGF-beta 2, 50 ng/ml CCN2/CTGF & 100 ng/ml CCN2/CTGF for 24 h. Densitometric analyses of Western Blot analyses shows the significant increase in alpha -actinin protein synthesis. Mean value of untreated cells (control) was set at 1. GAPDH was used to normalize protein intensity (n = 4; 50 ng CCN2/CTGF: *p = 0.029; 100 ng CCN2/CTGF: *p = 0.015; unpaired two-tailed t-test). (C) Scratch assay analyses show a significant increased migration rate for murine ON astrocytes after the treatment with ng/ml TGF-beta 2, 50 ng/ml CCN2/CTGF & 100 ng/ml CCN2/CTGF for 12 h. Mean value of migration rate of control cells was set to 100% (control: n = 15; TGF-beta 2: n = 12, **p = 0.008; 50 ng/ml CCN2/CTGF: n = 10, *p = 0.001; 100 ng/ml CCN2/CTGF: n = 4, **p = 0.0001). Data represented as mean ± SD. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35493079), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-724_rabbit-polyclonal-ctgf-ccn2-antibody-31020241683912.jpg)
![Immunohistochemistry: CTGF/CCN2 Antibody [NB100-724] - GFAP expression & synthesis in the ON & ONH in a murine glaucoma model. (A) GFAP immunoreactivity in the glial lamina of 1-month (green, upper panel) & 2 months (green, middle & lower panel) old beta B1-CTGF1 mice compared to WT controls. Immunoreactivity of GFAP not altered in 1-month old TG & WT animals (green, upper panel). 2 month old beta B1-CTGF1 mice showed an increased GFAP immunoreactivity compared to WT control (green, middle panel). Lower panel shows a magnified detail of the middle panel. Nuclei are stained w/ Dapi (blue). (B) Schmatic illustration of the optic nerve. A depicts region in the glial lamina where cross sections obtained. ONH (unmyelinated part) & ON (myelinated part) used for molecular analysis. (C) Quantification of immunohistochemical staining of GFAP in the glial lamina is not altered in 1 month old TG & WT animals (WT: n = 5; TG: n = 4). GFAP immunoreactivity is increased in 2 month old TG animals compared to WT littermates (WT: n = 10, TG: n = 13; *p = 0.039; two-tailed t-test compared to oretical mean of 1 (normalized control)). Mean value of WT animals (control) set at 1. (D) RT-PCR analyses revealed no alteration in the Gfap mRNA expression in the ON of 1-month (WT: n = 7; TG: n = 5) & 2 month old beta B1-CTGF1 mice (WT: n = 15; TG: n = 16) compared to WT controls. In the ONH the Gfap mRNA expression is increased in the 2 month old TG compared to WT animals (WT: n = 6, TG: n = 5; *p = 0.04). The mRNA expression of Gfap is not altered in 1 month old animals (WT: n = 6, TG: n = 5). Mean value of WT animals (control) set at 1. RPL32 used to normalize mRNA expression. Data represented as mean ± SEM. PRL, Prelaminar region; PSL, Postlaminar region; ON, optic nerve; ONH, optic nerve head. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35493079), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-724_rabbit-polyclonal-ctgf-ccn2-antibody-310202415523931.jpg)
![Immunohistochemistry: CTGF/CCN2 Antibody [NB100-724] - GFAP expression & synthesis in the ON & ONH in a murine glaucoma model. (A) GFAP immunoreactivity in the glial lamina of 1-month (green, upper panel) & 2 months (green, middle & lower panel) old beta B1-CTGF1 mice compared to WT controls. Immunoreactivity of GFAP not altered in 1-month old TG & WT animals (green, upper panel). 2 month old beta B1-CTGF1 mice showed an increased GFAP immunoreactivity compared to WT control (green, middle panel). Lower panel shows a magnified detail of the middle panel. Nuclei are stained w/ Dapi (blue). (B) Schmatic illustration of the optic nerve. A depicts region in the glial lamina where cross sections obtained. ONH (unmyelinated part) & ON (myelinated part) used for molecular analysis. (C) Quantification of immunohistochemical staining of GFAP in the glial lamina is not altered in 1 month old TG & WT animals (WT: n = 5; TG: n = 4). GFAP immunoreactivity is increased in 2 month old TG animals compared to WT littermates (WT: n = 10, TG: n = 13; *p = 0.039; two-tailed t-test compared to oretical mean of 1 (normalized control)). Mean value of WT animals (control) set at 1. (D) RT-PCR analyses revealed no alteration in the Gfap mRNA expression in the ON of 1-month (WT: n = 7; TG: n = 5) & 2 month old beta B1-CTGF1 mice (WT: n = 15; TG: n = 16) compared to WT controls. In the ONH the Gfap mRNA expression is increased in the 2 month old TG compared to WT animals (WT: n = 6, TG: n = 5; *p = 0.04). The mRNA expression of Gfap is not altered in 1 month old animals (WT: n = 6, TG: n = 5). Mean value of WT animals (control) set at 1. RPL32 used to normalize mRNA expression. Data represented as mean ± SEM. PRL, Prelaminar region; PSL, Postlaminar region; ON, optic nerve; ONH, optic nerve head. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35493079), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-724_rabbit-polyclonal-ctgf-ccn2-antibody-310202415535150.jpg)
![Immunocytochemistry/ Immunofluorescence: CTGF/CCN2 Antibody [NB100-724] - Analyses of ECM components in murine ON astrocytes following treatment w/ TGF-beta 2 & CCN2/CTGF. (A) Immunocytochemical staining against fibronectin (green, upper panel) showed a markedly increase following the treatment w/ 1 ng/ml TGF-beta 2 or 50 ng/ml CCN2/CTGF. Immunocytochemical staining against tropoelastin (green, lower panel) showed a pronounced increase after treatment w/ 1 ng/ml TGF-beta 2 or 50 ng/ml CCN2/CTGF. Nuclei stained w/ Dapi (blue). (B) Real-time RT-PCR analyses shows an intense upregulation of collagen 3 alpha 1, tropoelastin & fibronectin mRNA in murine ON astrocytes after treatment w/ 1 ng/ml TGF-beta 2, 50 ng/ml CCN2/CTGF or 100 ng/ml CCN2/CTGF for 24 h compared to untreated control cells (collagen 3 alpha 1: n = 3; TGF-beta 2 ***p = 0.0000004, 50 ngCTGF **p = 0.005, 100ngCTGF **p = 0.008; fibronectin: n = 6, TGF-beta 2 *p = 0.00004, 50 ng CTGF *p = 0.016, 100 ngCTGF *p = 0.05; elastin: n = 5, TGF-beta 2 *p = 0.026, 50 ng CTGF *0.04, 100 ng CTGF *p = 0.03). mRNA expression normalized to Gnb2l & mean value of control cells set at 1. (C) Western Blot analysis show an increase in protein synthesis of collagen 3 alpha 1, elastin & fibronectin in murine ON astrocytes after treatment w/ 1 ng/ml TGF-beta 2, 50 ng/ml CCN2/CTGF or 100 ng/ml CCN2/CTGF for 24 h compared to untreated control cells (collagen 3 alpha 1: n = 3, TGF-beta 2 *p = 0.03, 100 ngCTGF **p = 0.009; fibronectin: n = 5, **p = 0.005, 50 ngCTGF **p = 0.006, 100 ng CTGF *p = 0.02; tropoelastin: n = 5, TGF-beta 2 ***p = 0.0004, 50 ngCTGF **p = 0.002, 100 ngCTGF ***p = 0.00001). GAPDH & alpha -tubulin used to normalize protein synthesis & mean value of control cells set at 1. Right panel shows representative Western Blots for all three proteins. Data represented as mean ± SD. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35493079), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-724_rabbit-polyclonal-ctgf-ccn2-antibody-310202415532092.jpg)
![Immunocytochemistry/ Immunofluorescence: CTGF/CCN2 Antibody [NB100-724] - Increasing substratum stiffness causes alterations in murine ON astrocyte reactivity, actin cytoskeleton & CCN2/CTGF level. (A) Filamentous actin labeled by phalloidin (red, upper panel) is increased when murine ON astrocytes were cultured on substrates with higher stiffness (30 kPa, 60 kPa) compared to softer control (10 kPa). Increasing substratum stiffness leads to an enhanced formation of actin stress fibers. Immunoreactivity of CCN2/CTGF (green, middle panel) is markedly increased when murine ON astrocytes were grown on substrates with higher stiffness (30, 60 kPa) compared to softer control (10 kPa). Murine ON astrocytes show an enhanced GFAP protein synthesis (green, lower panel) when cultured on 30 or 60 kPa compared to 10 kPa. Nuclei were stained with Dapi (blue). (B) CCN2/CTGF protein synthesis is significantly increased in murine ON astrocytes grown on 60 kPa compared to 10 kPa (10 kPa: n = 5; 30 kPa: n = 5; 60 kPa: n = 5; *p = 0.04; unpaired two-tailed t-test). (C) Protein synthesis of GFAP (10 kPa: n = 6; 30 kPa: n = 6, **p = 0.005; 60 kPa: n = 4, *p = 0.04; unpaired two-tailed t-test) show an enhanced reactivity of murine ON astrocytes cultured on 30 kPa or 60 kPa compared to 10 kPa control. (D) Vimentin protein synthesis is significantly increased in murine ON astrocytes cultured on 60 kPa compared to 10 kPa (10 kPa: n = 4; 30 kPa: n = 4; 60 kPa: n = 3 ***p = 0.00002). Protein synthesis was normalized to alpha -tubulin & mean value of control (10 kPa) was set at 1. Data represented as mean ± SEM. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35493079), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-724_rabbit-polyclonal-ctgf-ccn2-antibody-31020241612698.jpg)
![Western Blot: CD44 Antibody [NBP1-31488] - Untreated (-) and treated (+) MDA-MB-231 whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with CD44 antibody. The observed M.W. is different from the predicted size. It is possibly due to post-translational modifications.](http://images.novusbio.com/fullsize/CD44-Antibody-Western-Blot-NBP1-31488-img0031.jpg "<b>Biological Strategies Validation. </b>Western Blot: CD44 Antibody [NBP1-31488] - Untreated (-) and treated (+) MDA-MB-231 whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with CD44 antibody. The observed M.W. is different from the predicted size. It is possibly due to post-translational modifications.")
![<b>Biological Strategies Validation. </b>Western Blot: CD44 Antibody [NBP1-31488] - Untreated (-) and treated (+) HeLa whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with CD44 antibody. The observed M.W. is different from the predicted size. It is possibly due to post-translational modifications.](http://images.novusbio.com/fullsize/CD44-Antibody-Western-Blot-NBP1-31488-img0033.jpg)
![Immunocytochemistry/Immunofluorescence: CD44 Antibody [NBP1-31488] - Analysis of methanol-fixed HeLa, using CD44 antibody (Green) at 1:500 dilution. Alpha-tubulin filaments were labeled with an alpha Tubulin antibody (Red) at 1:2000.](http://images.novusbio.com/fullsize/CD44-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-31488-img0016.jpg)
![Immunohistochemistry-Paraffin: CD44 Antibody [NBP1-31488] - Human cervical carcinoma. CD44 stained by CD44 antibody diluted at 1:500.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/CD44-Antibody-Immunohistochemistry-Paraffin-NBP1-31488-img0036.jpg)
![Immunohistochemistry-Paraffin: CD44 Antibody [NBP1-31488] - Human endometrial carcinoma. CD44 antibody diluted at 1:500. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min.](http://images.novusbio.com/fullsize/CD44-Antibody-Immunohistochemistry-Paraffin-NBP1-31488-img0026.jpg)
![Immunohistochemistry-Paraffin: CD44 Antibody [NBP1-31488] - Human pancreatic tumor, using CD44 antibody at 1:100 dilution. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min.](http://images.novusbio.com/fullsize/CD44-Antibody-Immunohistochemistry-Paraffin-NBP1-31488-img0035.jpg)
![Immunocytochemistry/ Immunofluorescence: CD44 Antibody [NBP1-31488] - CD44 antibody detects CD44 protein at cell membrane by immunofluorescent analysis.Sample: A431 cells were fixed in ice-cold MeOH for 5 min.Green: CD44 stained by CD44 antibody (NBP1-31488) diluted at 1:500.Blue: Fluoroshield with DAPI .](http://images.novusbio.com/fullsize/nbp1-31488_rabbit-polyclonal-cd44-antibody-91020242091445.jpg)
![Western Blot: CD44 Antibody [NBP1-31488] - Untreated (-) and treated (+) HeLa whole cell extracts (30 ug) were separated by 10% SDS-PAGE, and the membrane was blotted with CD44 antibody (NBP1-31488) diluted at 1:45000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody, and the signal was developed with Trident ECL plus-Enhanced.](http://images.novusbio.com/fullsize/nbp1-31488_rabbit-polyclonal-cd44-antibody-910202420104431.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: CD44 Antibody [NBP1-31488] - Non-transfected (–) and transfected (+) Wild-type (WT) and G CD44 knockout (KO) HeLa cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with CD44 antibody diluted at 1:7000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/nbp1-31488_rabbit-polyclonal-cd44-antibody-1610202419405756.jpg)
![<b>Orthogonal Strategies Validation. </b>Western Blot: CD44 Antibody [NBP1-31488] - Various whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with CD44 antibody diluted at 1:5000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody. Corresponding RNA expression data for the same cell lines are based on Human Protein Atlas program.](http://images.novusbio.com/fullsize/nbp1-31488_rabbit-polyclonal-cd44-antibody-1610202419414564.jpg)
![ELISA: Goat anti-Canine IgE Heavy Chain Secondary Antibody [NB7343] - Sandwich ELISA for total dog IgE measurement showing standard curve at 2 different coating antibody concentrations. Coating: 1ug/ml in carbonate buffer, pH 9.6. Standard: purified dog IgE, range: 156pg/ml to 15.000 pg/ml. Detection with secondary antibody (HRP-labeled) and TMB substrate. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/Goat-anti-Canine-IgE-Secondary-Antibody-ELISA-NB7343-img0001.jpg "ELISA: Goat anti-Canine IgE Heavy Chain Secondary Antibody [NB7343] - Sandwich ELISA for total dog IgE measurement showing standard curve at 2 different coating antibody concentrations. Coating: 1ug/ml in carbonate buffer, pH 9.6. Standard: purified dog IgE, range: 156pg/ml to 15.000 pg/ml. Detection with secondary antibody (HRP-labeled) and TMB substrate. This image was submitted via customer Review.")
![Dot Blot: Goat anti-Canine IgE Secondary Antibody [NB7343] - D.p. extracts have effects on MCs though the IgE-FcepsilonRI axis. SDS-PAGE of recombinants (300 ng) and Western blotting (168.8 ng, for rDer p 15; 143.8 ng of rDer p 18 per gel lane) of specific IgE in canine sera. Image collected and cropped by CiteAb from the following publication (//waojournal.biomedcentral.com/articles/10.1186/s40413-017-0154-3), licensed under a CC-BY license.. Using the HRP format of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Canine-IgE-Secondary-Antibody-Dot-Blot-NB7343-img0002.jpg)
![Western Blot: TLR4 Antibody [NBP2-24821] - Analysis of TLR4 using TLR4 antibody at 2 ug/mL on partial recombinant mouse TLR4 protein.](http://images.novusbio.com/fullsize/TLR4-Antibody-Western-Blot-NBP2-24821-img0001.jpg "Western Blot: TLR4 Antibody [NBP2-24821] - Analysis of TLR4 using TLR4 antibody at 2 ug/mL on partial recombinant mouse TLR4 protein.")
![Immunocytochemistry/Immunofluorescence: TLR4 Antibody [NBP2-24821] - U2OS cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with anti-TLR4 [NBP2-24821] at a 1:50 dilution overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:500 dilution. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse DyLight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/TLR4-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-24821-img0006.jpg)
![Immunohistochemistry-Paraffin: TLR4 Antibody [NBP2-24821] - Analysis of TLR4 in FFPE (A) normal and (B) tumor prostate sections using TLR4 antibody at 1:50 dilution. ICC analysis of TLR4 in formalin-fixed (C) Ramos and (D) 293 cells using antibody at 1:10 dilution. Data courtesy of Dr. Regina Gandour-Edwards.](http://images.novusbio.com/fullsize/TLR4-Antibody-Immunohistochemistry-Paraffin-NBP2-24821-img0002.jpg)
![Flow Cytometry: TLR4 Antibody [NBP2-24821] - Analysis using the Alexa Fluor (R) 488 conjugate of NBP2-24821. Staining of RAW cells were probed using 2 ug of TLR4 antibody (red) and 2 ug of isotype control antibody (green). Novus's TLR cell surface flow kit (10099K) was used for this test.](http://images.novusbio.com/fullsize/TLR4-Antibody-Flow-Cytometry-NBP2-24821-img0005.jpg)
![Flow Cytometry: TLR4 Antibody [NBP2-24821] - Cell surface analysis using TLR4 antibody. Mouse macrophage cells were probed using 1 ug of TLR4 antibody (red) and 1 ug of isotype control antibody (green). This antibody and PE-conjugated secondary were used for this test.](http://images.novusbio.com/fullsize/TLR4-Antibody-Flow-Cytometry-NBP2-24821-img0003.jpg)
![Western Blot: FoxP3 Antibody [NB600-242] - (1 ug/mL) staining of Human Muscle (A), (2 ug/mL) MOLT4 (B) and (1 ug/mL) negative control Pancreas (C) lysate (35 ug protein in RIPA buffer). Detected by chemiluminescence.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Western-Blot-NB600-242-img0010.jpg "Western Blot: FoxP3 Antibody [NB600-242] - (1 ug/mL) staining of Human Muscle (A), (2 ug/mL) MOLT4 (B) and (1 ug/mL) negative control Pancreas (C) lysate (35 ug protein in RIPA buffer). Detected by chemiluminescence.")
![Immunocytochemistry: FoxP3 Antibody [NB600-242] - (Treg) human blood cells gathered by cytospin and detected by FITC (A) and in phase contrast (B).](http://images.novusbio.com/fullsize/FoxP3-Antibody-Immunocytochemistry-Immunofluorescence-NB600-242-img0008.jpg)
![Immunohistochemistry: FoxP3 Antibody [NB600-242] - (8ug/ml) staining of paraffin embedded Human Spleen. Heat induced antigen retrieval with citrate buffer Ph 6, HRP-staining.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Immunohistochemistry-NB600-242-img0012.jpg)
![Flow Cytometry: FoxP3 Antibody [NB600-242] - Analysis of paraformaldehyde fixed Jurkat cells (blue line), permeabilized with 0.5% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (4 ug/mL). IgG control: Unimmunized goat IgG (black line) followed by Alexa Fluor 488 secondary antibody.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Flow-Cytometry-NB600-242-img0009.jpg)
![Immunofluorescence: FoxP3 Antibody [NB600-242] - Paraformaldehyde fixed U2OS cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (4 ug/mL), showing strong localization to nucleoplasm. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (4 ug/mL).](http://images.novusbio.com/fullsize/FoxP3-Antibody-Immunocytochemistry-Immunofluorescence-NB600-242-img0011.jpg)
![Control: FoxP3 Antibody [NB600-242] - Negative Control showing staining of paraffin embedded Human Spleen, with no primary antibody.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Control-NB600-242-img0013.jpg)
![Western Blot: CCR2 Antibody (3G7) [NBP2-35334] - Western blot analysis of CCR2 [3G7] in Molt4 lysate.](http://images.novusbio.com/fullsize/CCR2-Antibody-3G7-Western-Blot-NBP2-35334-img0007.jpg "Western Blot: CCR2 Antibody (3G7) [NBP2-35334] - Western blot analysis of CCR2 [3G7] in Molt4 lysate.")
![Immunohistochemistry-Paraffin: CCR2 Antibody (3G7) [NBP2-35334] - IHC analysis of formalin-fixed paraffin-embedded tissue section of human breast using CCR2 antibody (clone 3G7) at 5 ug/ml concentration. The glandular cells in the lobules showed a specific cytoplasmic-membranous immunostaining of CCR2.](http://images.novusbio.com/fullsize/CCR2-Antibody-3G7-Immunohistochemistry-Paraffin-NBP2-35334-img0006.jpg)
![Immunohistochemistry-Paraffin: CCR2 Antibody (3G7) [NBP2-35334] - IHC analysis of formalin-fixed paraffin-embedded tissue section of human HCC (hepatocellular carcinoma / malignant hepatoma) using CCR2 antibody (clone 3G7) at 5 ug/ml concentration. The cancer cells depicted specific punctate to diffused cytoplasmic-membranous immuno-staining of CCR2 protein.](http://images.novusbio.com/fullsize/CCR2-Antibody-3G7-Immunohistochemistry-Paraffin-NBP2-35334-img0003.jpg)
![Immunohistochemistry-Paraffin: CCR2 Antibody (3G7) [NBP2-35334] - IHC analysis of formalin-fixed paraffin-embedded tissue section of human esophageal squamous cell carcinoma (SCC) using CCR2 antibody (clone 3G7) at 5 ug/ml concentration. The cancer cells depicted specific cytoplasmic-membranous immunostaining, whereas the cells of tumor stroma were largely negative for CCR2 immunopositivity.](http://images.novusbio.com/fullsize/CCR2-Antibody-3G7-Immunohistochemistry-Paraffin-NBP2-35334-img0005.jpg)
![Western Blot: MBP Antibody (2H9) [NBP2-22121] - Total human brain lysate was separated by SDS-PAGE on a 12% gel and transferred to PVDF membrane. The membrane was then probed with anti-MBP antibody at 2 ug/mL and detected using an anti-mouse HRP labeled secondary antibody and chemiluminescent substrate.](http://images.novusbio.com/fullsize/MBP-Antibody-2H9-Western-Blot-NBP2-22121-img0008.jpg "Western Blot: MBP Antibody (2H9) [NBP2-22121] - Total human brain lysate was separated by SDS-PAGE on a 12% gel and transferred to PVDF membrane. The membrane was then probed with anti-MBP antibody at 2 ug/mL and detected using an anti-mouse HRP labeled secondary antibody and chemiluminescent substrate.")
![Immunocytochemistry/Immunofluorescence: Myelin Basic Protein Antibody (2H9) [NBP2-22121] - Immunofluorescence analysis of MSCS cells using Myelin Basic Protein mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.](http://images.novusbio.com/fullsize/Myelin-Basic-Protein-Antibody-2H9-Immunocytochemistry-Immunofluorescence-NBP2-22121-img0005.jpg)
![Immunohistochemistry-Frozen: MBP Antibody (2H9) [NBP2-22121] - Mouse brain cryosections were stained with anti-MBP (1:400) and anti-mouse Alexa Fluor 555 IgG. Staining specific, hardly any background. Magnification 1:20. Image from verified customer review.](http://images.novusbio.com/fullsize/MBP-Antibody-2H9-Immunohistochemistry-Frozen-NBP2-22121-img0009.jpg)
![Flow Cytometry: Myelin Basic Protein Antibody (2H9) [NBP2-22121] - Flow cytometric analysis of HepG2 cells using Myelin Basic Protein mouse mAb (green) and negative control (red).](http://images.novusbio.com/fullsize/Myelin-Basic-Protein-Antibody-2H9-Flow-Cytometry-NBP2-22121-img0004.jpg)
![Immunohistochemistry-Paraffin: Myelin Basic Protein Antibody (2H9) [NBP2-22121] - Immunohistochemical analysis of paraffin-embedded brain tissues using Myelin Basic Protein mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/Myelin-Basic-Protein-Antibody-2H9-Immunohistochemistry-Paraffin-NBP2-22121-img0006.jpg)
![Immunohistochemistry-Paraffin: Myelin Basic Protein Antibody (2H9) [NBP2-22121] - Immunohistochemical analysis of paraffin-embedded cerebellum tissues using Myelin Basic Protein mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/Myelin-Basic-Protein-Antibody-2H9-Immunohistochemistry-Paraffin-NBP2-22121-img0007.jpg)
![ELISA: Myelin Basic Protein Antibody (2H9) [NBP2-22121] - Red: Control Antigen (100ng); Purple: Antigen (10ng); Green: Antigen (50ng); Blue: Antigen (100ng).](http://images.novusbio.com/fullsize/Myelin-Basic-Protein-Antibody-2H9-ELISA-NBP2-22121-img0001.jpg)
![Simple Western: VPS34 Antibody [NB110-87320] - Simple Western lane view shows a specific band for VPS34 in 0.5 mg/ml of HepG2 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/VPS34-Antibody-Simple-Western-NB110-87320-img0006.jpg "Simple Western: VPS34 Antibody [NB110-87320] - Simple Western lane view shows a specific band for VPS34 in 0.5 mg/ml of HepG2 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.")
![<b>Genetic Strategies Validation. </b>Western Blot: VPS34 Antibody [NB110-87320] - ATG7 depleted SKBR3 cells show increased sensitivity to ATRA and the RARalpha agonist AM580. RARalpha , ATG5 and VPS34 Western blot analysis of control and the respective SKBR3 knockdown cells. GAPDH was used as a loading control. Image collected and cropped by CiteAb from the following publication (), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/VPS34-Antibody-Knockdown-Validated-NB110-87320-img0007.jpg)
![Western Blot: VPS34 Antibody [NB110-87320] - HepG2 whole cell lysates.](http://images.novusbio.com/fullsize/VPS34-Antibody-Western-Blot-NB110-87320-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: VPS34 Antibody [NB110-87320] - VPS34 antibody was tested at 1:200 in HeLa cells with FITC (green). Nuclei (Blue) were counterstained with Dapi (blue).](http://images.novusbio.com/fullsize/VPS34-Antibody-Immunocytochemistry-Immunofluorescence-NB110-87320-img0005.jpg)
![Western Blot: VPS34 Antibody [NB110-87320] - Celastrol regulates autophagy- & mitophagy-related gene expressions in neurons. SH-SY5Y cells treated with 0.1–1 μM celastrol for 4 h. (A) Real-time quantitative PCR results show that 1 μM celastrol treatment for 4 h enhanced mRNA expressions of phagophore induction genes Beclin 1 & Ambra1, phagophore elongation genes Atg7 & Atg12, & vacuole formation genes LC3A & Atg4B. (B) Western blot results of SH-SY5Y treated with 100–500 nM celastrol show celastrol (500 nM) increased in protein expressions of Beclin 1 & Vps34 (phagophore induction), Atg7 (phagophore elongation), LC3-II (vacuole formation), DJ-1, & PINK1 (mitophagy). Celastrol (500 nM) suppressed LRRK2 expression. (C) MPTP (10 mg/kg/day for 3 days, i.p.) but not celastrol (3 mg/kg/day for 3 days, i.p.) caused dopaminergic nerve terminal degeneration (tyrosine hydroxylase↓) & mitophagy inactivation (DJ-1↓ & PINK1↓) in the striatum of mice as compared to saline control. Celastrol cotreatment with MPTP reversed it as compared to MPTP. Data are given as the mean ± SEM (n = 3–5). p-value was determined using the Kruskal–Wallis test followed by Dunn’s multiple comparison post hoc test. * p < 0.05 compared with controls. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31906147), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-87320_rabbit-polyclonal-vps34-antibody-310202416205164.jpg)
![Immunohistochemistry-Frozen: CD8 Antibody (YTS105.18) [NB200-578] - CD8 alpha Antibody (YTS105.18) [NB200-578] - Staining of a mouse lymph node cryosection with rat anti-mouse CD19, clone 6D5 green in A and rat anti-mouse CD8, red in B. Merged image in C wih nuclei counterstained blue using DAPI. Low power](http://images.novusbio.com/fullsize/CD8-Antibody-YTS105-18-Immunohistochemistry-Frozen-NB200-578-img0006.jpg "Immunohistochemistry-Frozen: CD8 Antibody (YTS105.18) [NB200-578] - CD8 alpha Antibody (YTS105.18) [NB200-578] - Staining of a mouse lymph node cryosection with rat anti-mouse CD19, clone 6D5 green in A and rat anti-mouse CD8, red in B. Merged image in C wih nuclei counterstained blue using DAPI. Low power")
![Flow Cytometry: CD8 Antibody (YTS105.18) [NB200-578] - Staining of mouse spleen cells.](http://images.novusbio.com/fullsize/CD8-Antibody-YTS105-18-Flow-Cytometry-NB200-578-img0003.jpg)
![Immunohistochemistry-Frozen: CD8 Antibody (YTS105.18) [NB200-578] - CD8 alpha Antibody (YTS105.18) [NB200-578] - Staining of Mouse lymph node cryosection with CD8 Antibody and HRP-conjugated goat anti-rat IgG. Low power magnification.](http://images.novusbio.com/fullsize/CD8-Antibody-YTS105-18-Immunohistochemistry-Frozen-NB200-578-img0005.jpg)
![TRAF6 Inhibitor Peptide Set [NBP2-26506] - The TRAF6 inhibitory peptide inhibits osteoclast ifferentiation: RAW264.7 cells were plated on 24-well plates and stimulated with RANKL and M-CSF and incubated in the presence of different concentrations of control peptide (PTD) or the TRAF6. The TRAF6 at the concentration above 30 uM suppressed osteoclast differentiation.](http://images.novusbio.com/fullsize/TRAF6-Inhibitor-Peptide-Set-NBP2-26506-img0002.jpg "TRAF6 Inhibitor Peptide Set [NBP2-26506] - The TRAF6 inhibitory peptide inhibits osteoclast ifferentiation: RAW264.7 cells were plated on 24-well plates and stimulated with RANKL and M-CSF and incubated in the presence of different concentrations of control peptide (PTD) or the TRAF6. The TRAF6 at the concentration above 30 uM suppressed osteoclast differentiation.")